Want to see LCTX full AI Analyst Report?
LCTX Stock Chart & Stats
$1.71
-$0.04(-6.64%)
At close: 4:00 PM EST
$1.71
-$0.04(-6.64%)
Day’s Range― - ―
52-Week Range$0.93 - $2.09
Previous CloseN/A
Volume522.43K
Average Volume (3M)1.75M
Market Cap
$289.19M
Enterprise Value$360.49
Total Cash (Recent Filing)$53.38M
Total Debt (Recent Filing)$2.39M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 06, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding249,298,300
10 Day Avg. Volume913,058
30 Day Avg. Volume1,748,516
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)8.63
Price to Sales (P/S)26.40
P/FCF Ratio-19.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside309.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$15.63M
Bulls Say, Bears Say
Bulls Say
Scalable AlloSCOPE ManufacturingDemonstrated scalable AlloSCOPE manufacturing is a durable competitive advantage: reproducible master→working→clinical banking and math supporting millions of vials materially lower per-dose costs, enable off-the-shelf commercial economics, reduce supply constraints, and support margin sustainability across multiple programs.
Partner Validation For OpRegen (Roche/Genentech)Sustained clinical durability and active site expansion by Roche/Genentech is structural validation: it materially increases technical and commercial credibility, raises the probability of late‑stage success, and preserves access to sizeable milestone and partner funding that reduces Lineage's standalone development and commercialization burden.
Multi-year Cash Runway And Low LeverageA multi‑year runway into 2028 combined with low balance‑sheet leverage gives management time to achieve key technical and clinical inflection points without immediate distress. This structural liquidity window, plus contingent warrants/milestones, provides optionality to advance programs and negotiate non‑dilutive partnerships before large financing becomes necessary.
Bears Say
Negative Operating And Free Cash FlowPersistently negative operating and free cash flow signal structural reliance on external financing and partners. Even with a reported runway, continued burn forces periodic capital raises or partner deals, increasing dilution risk and constraining autonomous reinvestment capacity for manufacturing scale‑up or late‑stage trials over the medium term.
Deeply Negative ProfitabilityExtremely negative margins reflect a development‑stage cost structure where R&D and G&A outpace revenue; until one or more candidates are commercialized, profitability is unlikely to normalize. This entrenched loss profile reduces internal funding ability, raises dilution risk, and constrains long‑term financial resilience.
Program Scale And Partner Timing RiskMaterial program execution risks persist: OpRegen progress and associated disclosures depend on partner decisions, creating timing uncertainty for trials and milestone receipts. Separately, islet programs require large reactor scale and technical solutions. Together these structural and partner‑dependent risks can delay commercial timelines and financing triggers.
Lineage Therap News
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $0.93 and its highest was $2.09 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $289.19M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.01.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 249,298,300 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.03 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went down -3.759%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lineage Therap Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (309.36% Upside)
$7.00 (309.36% Upside)
Blogger Sentiment
Bullish
LCTX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 6.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.17%
12-Months-Change
Fundamentals
Return on Equity
-152.10%
Trailing 12-Months
Asset Growth
-1.99%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
LCTX Stock 12 Month Forecast
Average Price Target
$7.00
▲(309.36% Upside)
Technical Analysis
Amarin
―
Tvardi Therapeutics
―
DBV Technologies SA - American
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
13.98% Insiders
4.62% Mutual Funds
2.67% Other Institutional Investors
71.18% Public Companies and
Individual Investors